Upgrades According to TD Securities, the prior rating for Brookfield Renewable Partners LP (NYSE: BEP ) was changed from Buy to Action List Buy. Brookfield Renewable earned $0.03 in the second quarter, compared to $0.13 in the year-ago quarter. The current stock performance of Brookfield Renewable shows a 52-week-high of $41.95 and a 52-week-low of $30.85. Moreover, at the end of the last trading period, the closing price was at $30.94. Citigroup upgraded the previous rating for Agnico Eagle Mines Ltd (NYSE: AEM ) from Neutral to Buy. In the second quarter, Agnico Eagle Mines showed an EPS of $0.75, compared to $0.69 from the year-ago quarter. At the moment, the stock has a 52-week-high of $67.14 and a 52-week-low of $36.69. Agnico Eagle Mines closed at $41.43 at the end of the last trading period. For Bed Bath & Beyond Inc (NASDAQ: BBBY ), Odeon Capital upgraded the previous rating of Sell to Hold. In the second quarter, Bed Bath & Beyond showed an EPS of $3.22, compared to $0.04 from the year-ago quarter.
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW ) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. When asked about Charles River Laboratories International, Inc. (NYSE: CRL ), Cramer said, "It finally doesn’t have a high price-to-earnings multiple. I would actually start … Full story available on Benzinga.com
New Jersey, USA -- ( SBWIRE ) -- 09/28/2022 -- The latest study released on the Global Clinical Trials Market by AMA Research evaluates market size, trend, and forecast to 2027. The Clinical Trials market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.advancemarketanalytics.com/sample-report/17830-global-clinical-trials-market#utm_source=SBWireLal Key Players in This Report Include: Charles River Laboratories (United States), Quintiles IMS (United States), Eli Lilly and Company (United States), SGS SA (Switzerland), Paraxel International Corporation (United States), Pfizer Inc. (United States), Novo Nordisk A/S (United States), Clinipace (United States), Laboratory Corporation of America (United States), ICON Plc (Ireland), IQVIA (United States), Pharmaceutical Product Development, LLC(United States), Syneos Health (United States), PRA Health Sciences (United States), Wuxi AppTec (China).
Pharmaceutical Regulatory Affairs Market 2022 | Major Key Players included in this Report are LabCor, Charles River, Advent International and Many More with Development and Research Analysis by 2028 London, UK -- ( SBWIRE ) -- 09/06/2022 -- The global Pharmaceutical Regulatory Affairs market research report offers a thorough examination of the present and projected state of the market. The market research engaged in thorough primary and secondary research to gather all required market data. The latest report on the target market gives precise figures for the market size, share, production capability, demand, and growth for the upcoming year for the industry. Get a Sample Report of Pharmaceutical Regulatory Affairs Market @ https://www.intelligencemarketreport.com/report-sample/498696 According to the Pharmaceutical Regulatory Affairs market report, the market is quickly changing, and the impact is being investigated in both present and future circumstances. The research study takes into account the market size and value for each sort, industry, channel, and other area.
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI ) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. Wells Fargo lowered the price target on Charles River Laboratories International, Inc. (NYSE: CRL ) from $325 to $300. Charles River Laboratories shares fell 0.5% to close at $231.89 on Monday. Truist Securities raised Life Storage, Inc. (NYSE: LSI ) price target from $132 to $138. Life Storage shares rose 0.9% to close at $136.76 on Monday. Needham raised the price target on Nerdy, Inc. … Full story available on Benzinga.com
While many companies worry about the global economy, Charles River and Thermo Fisher are optimistic.